NCT06963398View on ClinicalTrials.gov

A Study of HS-10529 in KRAS G12D Patients With Advanced Solid Tumors

PHASE1Not yet recruitingINTERVENTIONAL
Enrollment

520

Participants

Timeline

Start Date

May 15, 2025

Primary Completion Date

April 30, 2029

Study Completion Date

August 30, 2029

Conditions
Advanced Solid Tumors
Interventions
DRUG

HS-10529

Participants in all subjucts will receive HS-10529

Sponsors
All Listed Sponsors
lead

Jiangsu Hansoh Pharmaceutical Co., Ltd.

INDUSTRY